글로벌 바이오 헬스큐어 기업 제넨셀


Anti-viral activity of compounds from Agrimonia pilosa and Galla rhois extract mixture



(주)제넨셀은 APRG64의 바이러스성 간염치료제 개발을 위해 지속적인 연구를 수행하고 있으며, 

중국 현지법인 설립을 통해 바이러스성 간염 치료제의 중국 임상시험 및 사업화를 추진하고 있습니다.


해당 논문은 경희대학교와의 공동연구를 통해 APRG64 14개 성분들의 HCV 억제 효능을 입증한 논문으로 

국제저명학술지 Bioorganic Chemistry (IF 3.929)에 게재되었으며, 

추후 APRG64의 임상시험 및 사업화에 기초자료로 활용될 예정입니다.




Hepatitis C virus (HCV) infection is a significant health problem, with a worldwide prevalence of about 170 million. Recently, the development of direct acting antiviral (DAA) as a therapeutic agent for HCV has been rapidly increasing. However, DAA has a side effect and is costly. Therefore, it is still necessary to develop a therapeutic agent to treat HCV infection using products. Agrimonia pilosa (AP) and Galla rhois (RG) are traditional medicines and are known to display therapeutic activity on various diseases. Notably, they have been reported to have an anti-viral effect on HBV and influenza virus infections. It is expected that anti-viral activity will increase when two extracts are mixed. To investigate their anti-viral activity, the expression level of HCV Core 1b and NS5A was measured. Remarkably, AP, RG, and their mixed compound (APRG64) strongly inhibited the expression of viral proteins, which led us to identify their metabolites. A total of 14 metabolites were identified using liquid chromatography mass spectrometry (LC-MS). These metabolites were evaluated for their anti-HCV activity to identify active ingredients. In conclusion, our results unveiled that anti-HCV activity of AP and RG extract mixture could lead to the development of a novel therapy for HCV infection. 


Keywords: Agrimonia pilosa, Galla rhois, HCV Core 1b, NSSA, LC-MS